Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Di Trapani, Mariano ^a   Bassi, Giulio ^a   Midolo, Martina ^a   Gatti, Alessandro ^a   Kamga, Paul Takam ^a   Cassaro, Adriana ^a   Carusone, Roberta ^a   Adamo, Annalisa ^a   Krampera, Mauro ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

B LYMPHOCYTE; CELL CULTURE; CROSS PRESENTATION; CYTOLOGY; EXOSOME; GENETICS; HUMAN; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; NATURAL KILLER CELL; T LYMPHOCYTE;

B-LYMPHOCYTES; CELLS, CULTURED; CROSS-PRIMING; CYTOKINES; EXTRACELLULAR VESICLES; HUMANS; KILLER CELLS, NATURAL; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES;

EID: 84963974153     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24120     Document Type: Article

References (62)

1. Friedenstein, A. J., Gorskaja, J. F. & Kulagina, N. N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental hematology 4, 267-274 (1976).
2. Zuk, P. A. et al. Human adipose tissue is a source of multipotent stem cells. Molecular biology of the cell 13, 4279-4295 (2002).
3. Erices, A., Conget, P. & Minguell, J. J. Mesenchymal progenitor cells in human umbilical cord blood. British journal of haematology 109, 235-242 (2000).
4. Moorefield, E. C. et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. Plos one 6, e26535 (2011).
5. Wang, Y., Chen, X., Cao, W. & Shi, Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nature immunology 15, 1009-1016 (2014).
6. Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell stem cell 13, 392-402 (2013).
7. Krampera, M. Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 25, 1408-1414 (2011).
8. Le Blanc, K. & Mougiakakos, D. Multipotent mesenchymal stromal cells and the innate immune system. Nature reviews. Immunology 12, 383-396 (2012).
9. Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nature reviews. Immunology 8, 726-736 (2008).
10. Corcione, A. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372 (2006).
11. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C. & Moretta, L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490 (2006).
12. Krampera, M. et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem cells 24, 386-398 (2006).
13. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell stem cell 2, 141-150 (2008).
14. Matysiak, M., Orlowski, W., Fortak-Michalska, M., Jurewicz, A. & Selmaj, K. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol 233, 106-111 (2011).
15. Mougiakakos, D. et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117, 4826-4835 (2011).
16. Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004).
17. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586 (2008).
18. Polchert, D. et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. European journal of immunology 38, 1745-1755 (2008).
19. Gonzalez-Rey, E. et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58, 929-939 (2009).
20. Rafei, M., Birman, E., Forner, K. & Galipeau, J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Molecular therapy: the journal of the American Society of Gene Therapy 17, 1799-1803 (2009).
21. Caplan, A. I. & Correa, D. The MSC: an injury drugstore. Cell stem cell 9, 11-15 (2011).
22. Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J. & Kessler, P. D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93-98 (2002).
23. Xiang, M. X., He, A. N., Wang, J. A. & Gui, C. Protective paracrine effect of mesenchymal stem cells on cardiomyocytes. Journal of Zhejiang University. Science. B 10, 619-624 (2009).
24. Park, J. H., Hwang, I., Hwang, S. H., Han, H. & Ha, H. Human umbilical cord blood-derived mesenchymal stem cells prevent diabetic renal injury through paracrine action. Diabetes research and clinical practice 98, 465-473 (2012).
25. Togel, F. et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. American journal of physiology. Renal physiology 292, F1626-1635 (2007).
26. Rani, S., Ryan, A. E., Griffin, M. D. & Ritter, T. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Molecular therapy: the journal of the American Society of Gene Therapy 23, 812-823 (2015).
27. Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nature reviews. Immunology 9, 581-593 (2009).
28. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. The Journal of cell biology 200, 373-383 (2013).
29. Carthew, R. W. & Sontheimer, E. J. Origins and Mechanisms of miRNAs and siRNAs. Cell 136, 642-655 (2009).
30. Wang, X. et al. Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis. Sci Rep 5, 13721 (2015).
31. Huffaker, T. B. et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2, 1697-1709 (2012).
32. Boldin, M. P. et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208, 1189-1201 (2011).
33. Alexander, M. et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun 6, 7321 (2015).
34. Lai, R. C. et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 4, 214-222 (2010).
35. Gatti, S. et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26, 1474-1483 (2011).
36. Bruno, S. et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. Plos one 7, e33115 (2012).
37. Li, T. et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 22, 845-854 (2013).
38. Zhu, Y. G. et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem cells 32, 116-125 (2014).
39. Lee, C. et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126, 2601-2611 (2012).
40. Conforti, A. et al. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev 23, 2591-2599 (2014).
41. Del Fattore, A. et al. Immunoregulatory effects of Mesenchymal Stem Cell-derived Extracellular Vesicles on T lymphocytes. Cell transplantation 24, 2615-2627 (2015).
42. Kilpinen, L. et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. J Extracell Vesicles 2, doi: 10.3402/jev.v2i0.21927 (2013).
43. Menard, C. et al. Clinical-grade mesenchymal stromal cells produced under various GMP processes differ in their immunomodulatory properties: Standardization of immune quality controls. Stem Cells Dev 22, 1789-1801 (2013).
44. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3, Unit 3 22 (2006).
45. Collino, F. et al. AKI Recovery Induced by Mesenchymal Stromal Cell-Derived Extracellular Vesicles Carrying MicroRNAs. Journal of the American Society of Nephrology: JASN 26, 2349-2360 (2015).
46. Bassi, G. et al. Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. Tissue engineering. Part A 21, 767-781 (2014).
47. Di Trapani, M. et al. Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. Stem Cells Dev 22, 2990-3002 (2013).
48. Di Trapani, M. et al. Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age. Stem Cells Dev 24, 132-143 (2015).
49. Augello, A. et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35, 1482-1490 (2005).
50. Chinnadurai, R., Copland, I. B., Patel, S. R. & Galipeau, J. IDO-independent suppression of T cell effector function by IFN-gammalicensed human mesenchymal stromal cells. J Immunol 192, 1491-1501 (2014).
51. Thery, C. et al. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nature immunology 3, 1156-1162 (2002).
52. Segura, E., Guerin, C., Hogg, N., Amigorena, S. & Thery, C. CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. Journal of immunology 179, 1489-1496 (2007).
53. Andreola, G. et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. The Journal of experimental medicine 195, 1303-1316 (2002).
54. Klibi, J. et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113, 1957-1966 (2009).
55. Galipeau, J. & Krampera, M. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 17, 125-127 (2015).
56. Di Trapani, M. et al. Immune Regulatory Properties of CD117 Amniotic Fluid Stem Cells Vary According to Gestational Age. Stem Cells Dev 24, 132-143 (2015).
57. Zhang, B. et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev 23, 1233-1244 (2014).
58. Li, J., et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nature immunology 14, 793-803 (2013).
59. Cossetti, C. et al. Extracellular vesicles from neural stem cells transfer IFN-gamma via Ifngr1 to activate Stat1 signaling in target cells. Mol Cell 56, 193-204 (2014).
60. Tan, C. Y. et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem cell research & therapy 5, 76 (2014).
61. Kordelas, L. et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28, 970-973 (2014).
62. Simonson, O. E. et al. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem cells translational medicine 4, 1199-1213 (2015).